Brief: Sanofi Exercises License Extension Option To Nurix’S Stat6 Program
02/06/2025 13:23
June 2 (Reuters) - Nurix Therapeutics Inc NRIX.O: SANOFI EXERCISES LICENSE EXTENSION OPTION TO NURIX’S STAT6 PROGRAM NURIX THERAPEUTICS INC - ELIGIBLE FOR $465 MILLION IN MILESTONES AND ROYALTIES NURIX THERAPEUTICS INC - TO RECEIVE $15 MILLION LICENSE EXTENSION FEE FROM SANOFI Source text: ID:nGNX62tHk2 Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis